Kymera Therapeutics (KYMR) Misses Q4 EPS by 18c

Kymera Therapeutics (NASDAQ: KYMR) reported Q4 EPS of ($0.97), $0.18 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $2.87 million versus the consensus estimate of $15 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook